title: Clearance of pathological antibodies using biomimetic nanoparticles.
abstract: Pathological antibodies have been demonstrated to play a key role in type II immune hypersensitivity reactions, resulting in the destruction of healthy tissues and leading to considerable morbidity for the patient. Unfortunately, current treatments present significant iatrogenic risk while still falling short for many patients in achieving clinical remission. In the present work, we explored the capability of target cell membrane-coated nanoparticles to abrogate the effect of pathological antibodies in an effort to minimize disease burden, without the need for drug-based immune suppression. Inspired by antibody-driven pathology, we used intact RBC membranes stabilized by biodegradable polymeric nanoparticle cores to serve as an alternative target for pathological antibodies in an antibody-induced anemia disease model. Through both in vitro and in vivo studies, we demonstrated efficacy of RBC membrane-cloaked nanoparticles to bind and neutralize anti-RBC polyclonal IgG effectively, and thus preserve circulating RBCs.
authors.affiliation: Department of Nanoengineering, Moores Cancer Center, and.
authors.forename: Jonathan A
authors.initials: JA
authors.lastname: Copp
authors.affiliation: Department of Nanoengineering, Moores Cancer Center, and.
authors.forename: Ronnie H
authors.initials: RH
authors.lastname: Fang
authors.affiliation: Department of Nanoengineering, Moores Cancer Center, and.
authors.forename: Brian T
authors.initials: BT
authors.lastname: Luk
authors.affiliation: Department of Nanoengineering, Moores Cancer Center, and.
authors.forename: Che-Ming J
authors.initials: CM
authors.lastname: Hu
authors.affiliation: Department of Nanoengineering, Moores Cancer Center, and.
authors.forename: Weiwei
authors.initials: W
authors.lastname: Gao
authors.affiliation: Department of Nanoengineering, Department of Ophthalmology and Shiley Eye Center, University of California, San Diego, La Jolla, CA 92093.
authors.forename: Kang
authors.initials: K
authors.lastname: Zhang
authors.affiliation: Department of Nanoengineering, Moores Cancer Center, and zhang@ucsd.edu.
authors.forename: Liangfang
authors.initials: L
authors.lastname: Zhang
mesh_terms: D000818:Animals; D000906:Antibodies / Q000276:immunology*; D057134:Antibodies, Neutralizing / Q000276:immunology / Q000494:pharmacology; D015551:Autoimmunity / Q000187:drug effects; D032701:Biomimetics; D004912:Erythrocytes / Q000276:immunology / Q000648:ultrastructure; D051379:Mice; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure
chemical_list: D000906:Antibodies; D057134:Antibodies, Neutralizing
keywords: autoantibody; immune therapy; nanomedicine; type II hypersensitivity reaction